Oblimersen sodium
As of the edition of 20 October 2026, Oblimersen sodium is an oligonucleotide: stopped in 2013; acts on BCL2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2013
- Kind
- Oligonucleotide
- Registered trials
- 43, 10 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue; Digestive system; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| BCL2 | Apoptosis regulator Bcl-2 | P10415 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 12 | 9 | 0 | 2 |
| Phase 2 | 22 | 16 | 0 | 6 |
| Phase 3 | 8 | 5 | 0 | 2 |
| All trials | 43 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Genta | Lead sponsor of trials | 2000 to now |